Clearside Biomedical Adds Board Member
This article was originally published in Scrip
Clearside Biomedical Inc., a company focused on therapies for blinding diseases of the eye, has appointed Richard J. Croarkin to its board of directors. Previously, Croarkin was chief financial officer (CFO) of Nestlé Health Science S.A. and served as senior vice president of finance, chief financial officer and corporate strategy officer at Alcon, Inc. Prior to Alcon, he was executive vice president and CFO of Nestlé Waters North America and before this, he held various global senior financial positions at Pepsico Inc.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.